A 65-year-old man initially underwent orthotopic liver transplant in our facility for end-stage liver failure due to infection with hepatitis C virus with resultant stage T3b Nx hepatocellular carcinoma. He is noted to have type O Rh+ blood. Donor liver was from a female patient of blood group type O Rh+. A total of 4 units of O Rh-packed red blood cells and 8 units of fresh frozen plasma were administered. No blood products were leukoreduced or irradiated.
His initial posttransplant course was notable for cytomegalovirus-positive conversion within the subsequent month. He had several other hospital admissions for dehydration, acute kidney injuries, rashes, and diarrhea. These symptoms are vague and not uncommon in transplant recipients, leading to uncertainty of diagnosis. GVHD, however, must be considered in such patients. At 3 months after transplant, he went to an outside hospital where he was found to have a white blood cell count of 0.1 × 10 9 /L with neutrophils of 0.04 × 10 9 /L, prompting his transfer to our transplant center. He had started treatment with fi lgrastin with discontinuation of dapsone and valgancyclovir. With his ongoing rash, he had a skin biopsy. His biopsy showed basal vacuolar changes with multiple ectopic keratinocytes, in association with a superfi cial perivascular and interstitial mixed infi ltrate with prominent melanophages. These fi ndings were consistent with graft-versus-host disease grade 2. Bone marrow biopsy showed aplastic anemia with overall pancytopenia. The biopsy was negative for cytomegalovirus, Epstein-Barr virus, and parvovirus. Cytogenetic studies, however, were signifi cant for evidence of chimerization with the fi nding of a 46,XX karyotype. This female karyotype in a male patient demonstrates complete graftversus-host disease with infi ltration of bone marrow with female cells most likely from the donor liver, leading to immunological attack of the graft bone marrow on our patient. Further testing was not performed as it would not change the patient's management and it was considered unethical to charge the patient for testing to verify the origin of the graft-versus-host disease (less likely blood products vs more likely liver transplant because of the larger lymphoid tissue).
The hematology/oncology and infectious disease services were consulted and the patient was cared for in the ICU. Throughout his hospital course, he was maintained on neutropenic precautions. He received supportive therapy with irradiated, leukocyte-reduced blood products as needed. Additionally, he was treated with high-dose methylprednisolone (1 mg/kg intravenously daily) as well as cyclosporine (10 mg/kg daily divided into every-12-hour dosing with target levels of 200-400 ng/mL). Filgrastin was discontinued as the patient was not responsive to it. He was treated with a 4-day course of antithymoglobulin. For anti-infectious prophylaxis, he was treated with caspofungin and piperacillin/tazobactam. A potential bone marrow transplant had been discussed but was ultimately decided against, given the high risk of inducing rejection of his orthotopic liver and low certainty of successful treatment.
Unfortunately, his course was complicated by infection with vancomycin-resistant Enterococcus, noted on blood cultures, and the patient was treated with daptomycin. He was initially receiving linezolid, but changed to daptomycin to reduce further pancytopenia. The patient continued to have severe protein malnutrition with ongoing diarrhea and gastrointestinal losses. Eventually the patient had septic shock develop, requiring mechanical ventilation for respiratory failure and multiple pressors. At that time, the patient's family elected to change his goals of care to comfort measures only, leading to his death.
Discussion
SOT-GVHD is a rare and lethal complication of transplant. 2 Published incidence rates for SOT-GVHD in liver transplant recipients are between 0.1% and 2%. 2, 4 Mortality rates are documented at 75% or greater in liver transplant recipients. 3, 5 There are 2 forms of SOT-GVHD. 6 In the fi rst and more common form, group O donor antibodies form against cells in patients with disparate blood group types. 6 The second form is cell mediated. 6 In this form, donor-derived T cells have a reaction to histoincompatible cells in the skin, liver, gastrointestinal tract, and bone marrow, leading to complications in these organs. 6 This particular form occurs through a multistep process. First, allograft-associated lymphocytes engraft and proliferate in the recipient's bone marrow. Next, donor-origin effector cells produce an immunological attack against immunologically disparate host tissue. 2 SOT-GVHD has an acute phase and a chronic phase. The acute phase is defi ned as occurring within the fi rst 100 days after transplant. 7 It typically occurs 1 to 11 weeks after transplant, 6 with a median onset of 33 days. 8 Chronic GVHD is defi ned as occurring more than 100 days after transplant. SOT-GVHD more commonly occurs after small-bowel and liver transplant, whereas lung and kidney transplants are rarer 3,5 causes (Table 1) . It is hypothesized that the risk factor for SOT-GVHD is related to the amount of lymphoid tissue in the donor organ. Other risk factors include greater HLA match between donor and recipient 3 and age greater than 65 years. 2, 4 SOT-GVHD typically is manifested by fever, diarrhea, rash, and multilineage cytopenia or pancytopenia. 2 The signs and symptoms are usually quite subtle 6 and are often confused with early infection in the immunocompromised state. GVHD most likely has many contributing factors. African Americans, for instance, have higher rates than do whites, Hispanics, and persons of Far-Eastern origin. 10 Additionally, cytomegalovirus infection is associated with chronic GVHD development in bone marrow recipients. 11 Diagnosis of SOT-GVHD is implied by biopsy-proven histologic features. 2 Confi rmation is made by showing greater than 1% 12 lymphocyte macrochimerism in peripheral blood. 2 Of note, diagnosis of SOT-GVHD is commonly delayed as the early signs and symptoms mirror those of more common problems such as viral illnesses. Donor chimerism studies should be obtained and GVHD diagnosis should be considered in all solid-organ transplant recipients with rash, diarrhea, liver dysfunction, and/or pancytopenias. The prognosis for patients with SOT-GVHD is poor. Death is usually due to infections associated with marrow suppression and multiorgan failure. Mortality rates for SOT-GVHD depend on the transplanted organ. Liver transplant patients have a mortality rate of 75%. [2] [3] [4] Lung transplant recipients have a mortality rate of 100%. Other solid-organ transplant patients are reported to have a 30% mortality. 2 Treatment of SOT-GVHD is controversial, with the limited evidence given the rarity and high mortality of cases precluding a strong evidence-based consensus on therapy. Several therapies have been proposed in published case reports and series (Table 2) . Treatment is usually initialized with high-dose corticosteroids. 2 It is likely that a second agent is necessary (second-line therapy) in addition to steroids, owing to the poor response to steroids alone. Additionally, antibiotic, antifungal, and antiviral prophylaxis should be started for potential septic complications in immunosuppressed patients. 14 In patients who do not respond to increasing immunosuppression, reduction of immunosuppressive agents to allow the recipient's immunological recovery and rejection of allograft donor T cells may be tried. Case reports have described successful therapies for GVHD related to liver transplant, including infl iximab, 15 etarnercept, 16 and alefacept. 17 Ultimately, because of the rarity of the disease, no evidence-based guidelines for therapies exist. However, it is possible that earlier diagnosis of SOT-GVHD may allow improved treatment response. For this reason, lymphocyte macrochimerism should be pursued in solid-organ transplant recipients in whom pancytopenia develops at any time, in particular, within the fi rst 2 months after transplant.
Conclusions
SOT-GVHD is a rare condition with subtle signs and symptoms, which often lead to delays in care and increased transplant recipients with rash, diarrhea, liver dysfunc- 
1%-2%
Extremely rare, 0.04% reported Extremely rare, case reports only mortality rate. We describe a case of this particular condition. This diagnosis should be considered in all transplant patients, particularly in patients with pancytopenia or fever and rash within the fi rst 2 months of transplant. Diagnosis is made with biopsy of tissue and lymphocyte macrochimerism. Treatment of this condition is controversial and should include high-dose corticosteroids, broad-spectrum antibiotics, antiviral agents, and antifungal agents. One should further consider reducing the patient's immunosuppressive agents and use of biological agents such as infl iximab. GVHD is an important disease of which intensive care nurses should be aware. Treatment must be instituted rapidly. This disease should be considered as a potential diagnosis in patients who have received transplants in the past and have vague signs and symptoms. CCN 
